Welcome to our dedicated page for Aeon Biopharma news (Ticker: AEON), a resource for investors and traders seeking the latest updates and insights on Aeon Biopharma stock.
AEON Biopharma, Inc. (AEON) is a clinical-stage biopharmaceutical company whose news flow centers on the development and financing of its lead asset, ABP-450 (prabotulinumtoxinA) injection. The company is focused on advancing ABP-450 as a proposed biosimilar to BOTOX (onabotulinumtoxinA) for therapeutic indications, using the FDA’s 351(k) biosimilar pathway. News updates often highlight progress in analytical studies, regulatory interactions, and capital structure initiatives that support this strategy.
Investors following AEON’s news can expect regular coverage of clinical and analytical milestones, such as reported positive biosimilarity data showing identical amino-acid sequencing and highly similar functional characteristics compared with BOTOX. The company also issues releases about scheduling and outcomes of key FDA meetings, including Biosimilar Biological Product Development (BPD) Type 2a meetings to review its analytical development plan and initial biosimilarity data.
Another major theme in AEON’s news is financing and balance sheet management. The company has announced a PIPE private placement with institutional investors and an Exchange Agreement with Daewoong Pharmaceutical to convert senior secured convertible notes into equity, a new note due 2030, and warrants. These transactions are described as intended to reduce outstanding debt and reshape the capital structure, subject to stockholder approval and other conditions. AEON also reports on NYSE American listing compliance matters and the acceptance of its plan to regain compliance with continued listing standards.
In addition, AEON issues news about corporate governance and compensation, including the appointment of a new President and Chief Executive Officer, inducement equity awards under its 2025 Inducement Incentive Plan, and RSU grants to new employees. For readers tracking AEON, the news page provides a consolidated view of developments in its biosimilar program, regulatory pathway, financing arrangements, and leadership changes. Bookmarking this page allows users to monitor how scientific data, FDA interactions, and capital markets activity shape the company’s progress with ABP-450.
AEON (NYSE American: AEON) announced an accepted poster presentation at the 2026 American Academy of Neurology Annual Meeting in Chicago, April 18–22, 2026.
The poster (abstract #4146) presents analytical primary structure comparability between ABP-450 (prabotulinumtoxinA) and onabotulinumtoxinA (Botox), reporting 93.5%–99.3% peptide sequence coverage and no variant peptides across multiple lots. Presenter: Chad K. Oh, M.D.; Date: April 22, 2026; Time: 11:45 am–12:45 pm CT.
AEON (NYSE: AEON) held its scheduled BPD Type 2a meeting with the FDA on Jan. 21, 2026 and is awaiting the official meeting minutes, expected within approximately 30 days, which the company says will inform next steps for development of ABP-450, a biosimilar to BOTOX.
On the same day shareholders approved the November transactions, enabling the Daewoong note exchange to close and substantially reduce outstanding debt, and clearing the way for the second closing of the PIPE financing on or around Jan. 27, 2026 subject to customary closing conditions.
AEON Biopharma (NYSE: AEON) reported inducement grants totaling 392,158 restricted stock units (RSUs) to newly hired non-executive employees, approved under the company’s 2025 Inducement Incentive Plan.
The grants have a grant date of December 11, 2025, vesting commencement dates in December 2025, and vest 25% annually over four years. Awards are subject to the Inducement Plan and individual RSU agreement terms and were issued as inducement material under Section 711 of the NYSE American Company Guide.
AEON Biopharma (NYSE: AEON) announced a definitive exchange with Daewoong on Dec 15, 2025 converting $15 million of convertible notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash‑exercise warrant for 8 million common shares. The warrants, if exercised, could provide over $8 million of additional cash proceeds. The transaction is subject to stockholder approval and is expected to eliminate more than 90% of AEON’s outstanding debt, altering the company’s capital structure and Daewoong’s strategic alignment with AEON.
AEON (NYSE American: AEON) announced a first closing of its previously announced PIPE on Nov 18, 2025 that generated approximately $1.79 million in proceeds. The company said the proceeds, together with anticipated second-closing funds, will support its analytical program and are expected to accelerate ABP-450 biosimilar development by up to six months.
AEON also disclosed the FDA proposed a new date of Jan 21, 2026 for its BPD Type 2a meeting (previously Nov 19, 2025); the meeting will review analytical plans and initial biosimilarity data, and the FDA did not cite scientific or program-related issues in the scheduling change.
AEON (NYSE:AEON) reported Q3 2025 results and a business update on Nov 14, 2025 highlighting positive analytical biosimilarity data for ABP-450 and strategic financings. LC-MS showed a 100% amino-acid sequence match to BOTOX across visible portions and 93–99% sequence coverage across five proteins; the analytical package was submitted ahead of an FDA Type 2a meeting on Nov 19, 2025.
The company announced a $6 million PIPE and a proposed Daewoong note exchange expected to cut outstanding debt by >90%, accelerate the ABP-450 program by up to six months, and extend cash runway into Q2 2026. Cash was $5.9 million at Sept 30, 2025 (pre-Pipe).
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has granted 102,880 restricted stock units (RSUs) to newly hired non-executive employees. The RSUs were approved under the AEON 2025 Inducement Incentive Plan, with a grant and vesting commencement date of May 21, 2025. The RSUs will vest over a four-year period, with 25% vesting annually. These awards serve as employment inducements and comply with Section 711 of NYSE American LLC Company Guide.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin complex treatments, has announced its participation in the upcoming Aegis Capital Corp. 2025 Virtual Conference. The company's President and CEO, Rob Bancroft, will deliver a corporate overview presentation on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. AEON's focus is on developing treatments for multiple therapeutic indications using their botulinum toxin complex technology.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has received acceptance from NYSE American for its compliance plan. The exchange has granted AEON until August 3, 2026 to meet minimum market capitalization and stockholders' equity requirements under Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.
During this period, AEON will undergo periodic reviews to assess progress toward compliance goals. If the company fails to regain compliance by the deadline or doesn't show sufficient progress, NYSE American may initiate delisting proceedings.